When do the patents on SODIUM FLUORIDE F 18 expire, and when will SODIUM FLUORIDE F 18 go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nih Nci Dctd	SODIUM FLUORIDE F 18	sodium fluoride f-18	INJECTABLE;INTRAVENOUS	022494-001	Jan 26, 2011		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 27, 2026

Sodium Fluoride F 18 (18F-NaF) Investment Scenario and Patent/Regulatory Fundamentals: Exclusivity, Competitive Risks, and Commercial Outlook

18F-sodium fluoride (sodium fluoride F 18, NaF-18) is an FDA-regulated radiopharmaceutical whose U.S. market access is constrained by supply-chain capacity, cyclotron production/QA release, and limited product and process patent coverage that typically sits behind FDA-listed manufacturing and labeling. Investment fundamentals hinge less on blockbuster-style chronic exclusivity and more on (i) production economics and throughput, (ii) facility licensing and radiation safety compliance, (iii) FDA Drug Shortage/quality enforcement risk, and (iv) substitution or workflow changes in imaging volume (bone metastasis assessment by PET).

Because sodium fluoride F 18 is a radiopharmaceutical with manufacturing and release controls that are hard to scale quickly, capital decisions tend to track cyclotron-to-distribution logistics and batch yield. Patent leverage, where present, is usually about specific manufacturing/process or formulation/packaging details rather than broad active-ingredient exclusivity.

What is Sodium Fluoride F 18 (18F-NaF) and what drives demand?

Direct answer: Demand is driven by PET utilization for bone imaging, patient referrals for staging/restaging in oncology, and operational availability within narrow regional delivery windows.

Clinical use and payer demand drivers

Standard clinical role: PET imaging for detection of bone metastases and assessment of skeletal disease burden, commonly in oncology workflows where PET is used to replace or complement bone scans.
Utilization is impacted by:
- PET center penetration and scanner capacity
- Radiotracer availability and timely delivery
- Physician preference and clinical guideline alignment
- Competing workflows (e.g., alternative PET bone agents) and competing modality shifts (bone scan SPECT, PET with other tracers)

Operational demand drivers

NaF-18 is time-sensitive; lot release and delivery timing matter.
Supply disruptions create immediate substitution pressures (centers seek alternative radiotracers or reschedule).

What is the FDA regulatory status of sodium fluoride F 18 (18F-NaF) in the U.S.?

Direct answer: It is an FDA-regulated radiopharmaceutical. U.S. commercial supply depends on the applicant’s marketing authorization and ongoing compliance with current good manufacturing practice (cGMP), radiopharmaceutical sterility and radionuclidic purity/quality specifications, and drug labeling.

Key regulatory mechanics for investment

Radiopharmaceuticals are highly sensitive to:
- Production deviations and batch failures
- Quality control turnaround times (radionuclidic purity, identity, sterility, pyrogen/endotoxin, residual solvents or impurities as specified)
- Radiation safety and shipping compliance (DOT/IATA where relevant)
Market participation is constrained by the ability to maintain consistent release specs and manage decay/time windows without losing sellable yield.

Orange Book status: where it matters

For most radiopharmaceutical business cases, the practical “exclusivity landscape” is tied to:

Whether the reference listed drug and application is still under active exclusivity periods (rare for fully mature radiotracers)
Whether there are listed patents in the FDA publication systems that create barriers for subsequent applicants
Whether new entrants must rely on generic-like approvals versus riskier abbreviated pathways

(For a precise Orange Book patent-by-patent listing, this requires the specific NDA/BLA reference product entry number and its listed patents; those details are not provided in the input.)

When does sodium fluoride F 18 lose exclusivity in the U.S., and what timelines matter?

Direct answer: Investors should treat exclusivity for mature radiotracers as likely near-term limited, with more value in process continuity and manufacturing capacity than in active monopoly periods.

How to think about “exclusivity” in radiopharmaceuticals

Even when patents exist, the economic “effective exclusivity” is often governed by:

Cyclotron availability and utilization
Specialty sterile radiochemistry capacity
Distribution logistics and regional coverage
Batch success rate and QC pass-through yield

Typical timeline risk

For long-lived therapeutic monopolies, timelines are defined by patent expirations plus regulatory exclusivity.
For radiopharmaceuticals, the more binding constraint is operational readiness. New capacity can enter faster than patent expirations if manufacturing pathways are not blocked and regulatory pathways permit.

(Exact expiration dates cannot be derived from the prompt; no specific NDA/BLA, patent numbers, or Orange Book listings were provided.)

What patents protect sodium fluoride F 18, and how strong is the patent estate?

Direct answer: Patent protection for NaF-18 typically clusters around manufacturing and radiochemical process parameters, quality/release methods, and container/packaging or delivery system details rather than broad active-ingredient composition claims.

Common patent categories investors should map

Manufacturing methods: improved radiochemical synthesis, purification, target water handling, stability during preparation, and process control methods that increase yield or reduce impurities.
Quality testing and release methods: assays for identity, radiochemical purity, radionuclidic purity, sterility, endotoxin, and related QC procedures.
Packaging and container-closure systems: container materials and configurations that preserve stability and meet specification across time.
Dosage delivery: aspects that maintain dose accuracy, minimize adsorption/loss, and improve administration workflow.

Patent strength assessment framework (actionable)

In radiopharmaceuticals, “strong” patent estates usually have at least one of:

Claims that are difficult to design around (process steps integrated into core manufacturing)
Broad method coverage that fits multiple cyclotron-to-QC workflows
Enforcement history or licensing practice confirming active value capture

“Weak” estates usually:

Cluster narrowly in specific example embodiments
Are easy to route around by changing target handling or purification order
Have limited remaining life or low claim breadth

(Definitive strength requires a patent-by-patent dataset including application/patent numbers, assignees, jurisdiction, remaining term, claim scope, and litigation posture; none were included in the prompt.)

Which companies supply sodium fluoride F 18, and what is the competitive landscape?

Direct answer: Supply is dominated by radiopharmacy networks and manufacturers with cyclotron and radiochemistry expertise; competition is often structural (facility access and throughput) rather than purely commercial marketing.

Competitive dimensions investors should evaluate

Geographic coverage and delivery time reliability
Production capacity and batch success rates
Contracting model: hospital direct sales versus distributor or radiopharmacy network agreements
Service-level guarantees (availability within specific time windows)
Ability to withstand cyclotron maintenance downtime and QC bottlenecks

What formulations, packaging, and manufacturing methods are protected for 18F-NaF?

Direct answer: Protected subject matter most often concerns process and stability during preparation and delivery, not “formulation” in the traditional oral-drug sense.

How to translate that into diligence

Confirm manufacturing pathway compatibility:
- Target preparation and chemistry approach
- Filtration/purification steps
- Final sterile fill and container material compatibility
Confirm stability and specification maintenance across distribution time:
- Radionuclidic purity maintenance
- Radiochemical purity retention
- Adsorption losses and container effects
Confirm QC release workflow speed:
- Turnaround time and staffing
- Trending of sterility and endotoxin failures

What generic or biosimilar entry risks exist for sodium fluoride F 18?

Direct answer: “Generic entry” risk exists where regulatory pathways allow marketing of equivalent radiopharmaceutical products and no enforceable blocking patents cover core manufacturing steps.

Primary entry bottlenecks

Chemistry manufacturing and controls (CMC) comparability at scale
Radiation safety and supply chain reliability
Lot release documentation and compliance history
Practical ability to deliver dose on time to PET centers

Main legal/IP risk drivers

Patent wall around key manufacturing steps or release methods
Litigation that delays market entry or triggers settlements
Regulatory delays caused by CMC deficiencies or QC nonconformance

(Paragraph IV challenges are framework-dependent and require known Orange Book listings and patent numbers for the relevant U.S. reference product. None are available in the prompt.)

What patent litigation or settlements affect sodium fluoride F 18?

Direct answer: Litigation risk should be assessed by identifying all Orange Book-listed patents tied to the marketed U.S. reference product and then mapping their litigation history by jurisdiction and assignee.

No specific litigation docket, settlement terms, or court decisions were provided in the prompt; therefore, a case-by-case litigation map cannot be produced without risking error.

What is the investment thesis: capacity-led growth versus exclusivity-led growth?

Direct answer: NaF-18 economics are typically capacity-led. Exclusivity-led upside is usually limited and secondary to operational reliability.

Core value drivers

Cyclotron utilization and batch yield
- Throughput reduces unit costs and improves fill rates.
QC pass rate and release speed
- Lower batch failure reduces lost sellable activity.
Regional logistics and delivery SLAs
- Reliable delivery protects contracted volumes.
Contracting power with PET centers
- Multi-site agreements reduce volatility and smooth demand.

Where IP can still matter

If there is enforceable patent coverage for key process or QC steps, investors can underwrite margin protection against “fast follow” entrants.
If patents are narrow or near expiration, IP functions more as a timing and licensing lever than as a long-term monopoly.

Revenue exposure: what volume and margin sensitivities matter most?

Direct answer: The most sensitive metrics are dose availability, sellable yield per run, and gross margin after QC, staffing, and shipping.

Sensitivity drivers

Cyclotron downtime increases missed delivery windows and reduces sellable yield.
QC failures cause complete batch loss due to inability to release within time-dependent constraints.
Distribution delays reduce usable radionuclide activity, lowering effective revenue per batch.

Capital allocation risk

New production sites require upfront CapEx and lead times for:
- Facility buildout
- Radiation safety commissioning
- Validation of QA/QC release
- Workforce training
The payback depends on stable regional demand and minimizing batch failures during ramp-up.

Commercial and regulatory execution risks: what can break the business case?

Direct answer: Supply interruption, quality noncompliance, and CMC release failures are the principal downside risks.

Quality and compliance failure modes

Sterility or endotoxin out-of-spec events
Radionuclidic purity or radiochemical purity failures
Documentation gaps in batch records or QC trending
Shipping excursions or chain-of-custody deviations

Regulatory enforcement risk

FDA inspections and warning letters can disrupt manufacturing and delay distribution.
Drug shortage communications and enforcement actions can affect pricing and contracting.

How does sodium fluoride F 18 compare with competing PET bone tracers?

Direct answer: NaF-18 competes on availability, cost per administered dose, and clinical workflow integration; differentiators are often supply reliability and logistics rather than clinical superiority.

Key comparison axes for investors:

Center preference and protocol adherence
Acquisition and contracting terms
Delivery timing and reliability (affects scan scheduling)
Production complexity and supplier robustness

(Exact head-to-head clinical and labeling comparisons require product-specific label and clinical guideline data not provided in the prompt.)

Key patent-mapped diligence checklist for investors (actionable, radiopharmaceutical specific)

Direct answer: Build the market entry risk map by linking three datasets: the FDA reference product identity, its listed patents, and the manufacturing/process claim coverage.

What to map

Identify the U.S. reference listed drug (RLD) for 18F-NaF.
Extract all FDA-listed patents tied to the RLD and record:
- Patent number, assignee, priority and expiration dates
- Claim categories (composition, method of manufacture, QC/release, packaging)
- Jurisdictions with active term
For each likely entrant:
- Determine whether their manufacturing process could avoid each core patent claim element.

(Orange Book patent extraction cannot be completed from the prompt.)

Key Takeaways

Sodium fluoride F 18 is an FDA-regulated, time-sensitive PET radiopharmaceutical where business fundamentals are primarily capacity-led: cyclotron utilization, dose release throughput, QC pass rate, and on-time logistics.
Patent leverage, when present, typically targets manufacturing/process and quality-release details rather than broad composition exclusivity, so effective competition barriers often track “how hard it is to manufacture consistently,” not only patent clocks.
Exclusivity-led upsides are likely limited for mature radiotracers; investors should underwrite operational reliability and supply-chain defensibility.
The highest downside risks are batch release failures, quality compliance events, and supply disruptions that directly convert to missed scan opportunities and lost contracted volumes.
A complete patent and litigation view requires mapping the FDA RLD’s listed patents and their remaining terms; those specifics are not included in the input, so no patent-expiration or Paragraph IV/Orange Book timelines are asserted here.

FAQs

Is sodium fluoride F 18 FDA-approved for PET imaging, and what labeling constraints govern use?
What manufacturing controls matter most for 18F-NaF quality release (radiochemical purity, radionuclidic purity, sterility)?
How quickly can a new cyclotron-based radiopharmacy enter the sodium fluoride F 18 supply market?
Does sodium fluoride F 18 face FDA shortage or enforcement risk, and what triggers it?
What operational KPIs best predict profitability for a NaF-18 producer?

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. Drugs@FDA. U.S. Food and Drug Administration.
FDA. Current Good Manufacturing Practice (CGMP) Regulations. U.S. Food and Drug Administration.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for SODIUM FLUORIDE F 18